Swedish companies' R&D investments increasing – still at the top in the EU

17 February 2025

Swedish companies are increasingly investing in R&D. In 2023, the corporate sector's expenditure on its own R&D amounted to 166.1 billion Swedish kronor ($14.8 billion), an increase of 14.4 billion kronor or 9.4% compared to 2021 (in constant prices).

The investments corresponded to 2.68% of gross domestic product (GDP) and this places Sweden at the top among European Union (EU) countries in terms of business research intensity, according to a posting on the website of the country’s pharma trade group Lif.

With the exception of 2021, Swedish companies have been the most R&D-intensive in the EU over the past decade.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical